ABSTRACT. To explore the possibility that intraamniotic is impractical to treat tachyarrhythmia both because multiple administration of digoxin is an effective treatment regimen intrafetal injections are required and because fetal plasma digoxin for fetal tachyarrhythmia, we injected digoxin into the concentrations are difficult to control. To determine whether amniotic fluid cavity of pregnant sheep and examined the intraamniotic administration of digoxin might effectively treat time course of digoxin distribution to the fetal and maternal fetal tachyarrhythmia, we injected digoxin into the amniotic plasma compartments. Animals were studied in two groups cavity of pregnant sheep and measured the distribution of digoxin according to digoxin dosage: 0.7-1.8 nmol/kg fetal body wt from the amniotic cavity to the fetal and maternal plasma in the high-dose group (n = 6) and 0.1-0.6 nmol/kg fetal compartments. body wt in the low-dose group (n = 14). Within 1 h, plasma digoxin concentrations in the high-dose and low-dose L, and at 24 h they were 2.3 nmol/L (n = 1) and 1.8 f 1.2 gestation. Surgical techniques to implant catheters into the ewe nmol/L, respectively. Peak maternal digoxin levels were and the fetus have been described in detail previously (14). about one-tenth fetal values in the high-dose group and Briefly, after spinal anesthesia was induced in the ewe with 4 mL undetectable in the low-dose group. Fetal digoxin concen-of 1 % tetracaine hydrochloride, polyvinyl catheters were inserted trations were significantly greater in the descending aorta into a peripheral artery and vein. The ewes were given an i.v.
pressure and heart rate were not significantly different was administered intravenously in doses of 100 mg every 15-20 from control at any time after digoxin administration. min. Through a midline incision, the uterus was exposed and These results demonstrate that digoxin is rapidly taken up the fetal hindlimbs identified. Polyvinyl catheters were inserted into the fetal circulation from the maternal amniotic cavity. into a peripheral artery and vein of each hindlimb and advanced The exact mechanism whereby this occurs is unknown, but to the descending aorta and inferior vena cava. In seven fetuses, transplacental transfer from the maternal circulation is not an 8 F polyvinyl catheter was inserted suprapubically into the involved. Our findings suggest that intraamniotic admin-urinary bladder through a purse-string suture (15) . A 3.5 F istration of digoxin may be an alternative treatment for multiple side-hole catheter was introduced into a distal cotylefetal tachyarrhythmias when direct administration of an-donary tributary of the umbilical vein and advanced proximally tiarrhythmic agents is ineffective or produces maternal toward the fetal body in 12 animals. Two catheters were also toxicity. (Pediatu Res 27: 282-285, 1990) inserted into the amniotic cavity, one near the cervix and the other in the uterine horn. All catheters were exteriorized at the ewe's flank where they were protected in a cloth pouch sewn to the ewe's skin. Potassium penicillin (1 million U) and gentamicin Fetal tachyarrhythmia, especially supraventricular tachy-(50 mg) were administered to the ewe and into the amniotic is a cause of congestive heart failure and fetal death cavity on the day of surgery and every ~o s~o~~ associated with nonimmune hydrops fetalis. Digoxin administraExperimental protocol. One to 3 d after surgery, we studied tion to pregnant women has been successful in the treatment of the distribution of digoxin in the maternal-fetal unit. Digoxin fetal tachyarrhythmia (1) (2) (3) (4) (5) (6) (7) (8) . Previous studies have demonstrated was diluted in 20 mL saline and injected into the amniotic that digoxin easily crosses the placenta in the human (9, 10) and catheter located near the cervix. Initially we injected digoxin at sheep (1 1). However, high concentrations of digoxin are required an estimated dose of 1 nmol/kg fetal body wt in six fetuses (high dose). This increased fetal plasma digoxin concentrations to in the mother because placental transfer is variable ( 1 -1 1 after collection, decanted, and stored at 4°C until they were Supported in part by NIH Grant GM2669 1.
assayed. Urine and amniotic fluid samples were also assayed.
Digoxin concentration in each sample was measured by radioimmunoassay (Amerlix Digoxin RIA kit Amersham Co., Arlington Heights, IL); this assay does not detect digoxin-like immunoreactive substance (16) . Fetal arterial blood gases, pH, and hemoglobin were measured daily using a blood gas analyzer (1 58 pH/blood gas analyzer, Corning Medical, Medfield, MA) and a Hemoximeter (OSM2, Radiometer, Copenhagen, Denmark). In 15 animals, fetal vascular pressures were measured with Statham P23Dc transducers (Statham Instruments, Santa Ana, CA), and heart rate was recorded continuously with a Beckman cardiotachometer (Beckman Instruments Inc., Fullerton, CA) triggered by the arterial pulse wave and a Beckman type RM direct writing recorder. All pressures were corrected using amniotic pressure as a zero reference. Data were analyzed by paired t test with correction for multiple comparisons. All values are expressed as mean + SD.
RESULTS
In the fetuses at the beginning of the study, pH was 7.35 + 0.03, Pco2 was 7.6 + 0.5 kPa, and Po2 was 2.4 + 0.5 kPa. Four hours after digoxin administration, pH, Pco~, and Po2 were 7.33 + 0.09, 7.8 + 1.1 kPa, and 2.5 + 0.5 kPa, respectively. These values were not significantly different from control values.
Before digoxin administration, digoxin immunoreactivity could not be detected in fetal and maternal plasma or amniotic fluid, nor in fetal urine. Figure 1 depicts mean fetal digoxin concentrations in aortic plasma in both high-and low-dose groups. In the high-dose group, digoxin concentrations rose rapidly to 18.2 a 15.0 nmol/L at 1 h and were maintained for 6 h. Digoxin concentrations in the low-dose group also increased rapidly, reaching 2.7 + 0.8 nmol/L within 1 h and remaining elevated for at least 6 h. There were no significant differences between values at 1, 4, and 6 h in either group.
As shown in Table 1 , the average peak concentrations of digoxin in fetal plasma in the high-and low-dose groups were 20.0 + 10.9 and 3.4 + 0.7 nmol/L, respectively. The time to reach the peak concentration varied in each case, and had no correlation with fetal arterial pH, Po2, or Pco2. There was also no statistically significant relationship between digoxin dose, peak digoxin concentration, or arterial blood gases. Peak digoxin concentrations in the ewe's plasma were about one-tenth of fetal concentrations in the high-dose group, but were below the assay detection limit in 10 of 11 ewes in the low-dose group. We also measured the digoxin concentration of amniotic fluid in 11 animals and calculated the ratio of fetal arterial digoxin concentration to that of amniotic fluid. These ratios, expressed as percentages, ranged from 0.4 to 4.9% in the high-dose group and from 0.7 to 3.1 % in the low-dose group.
Sampling was not complete in the high-or low-dose studies. However, sufficient fetal arterial samples were obtained at early time points to give some indication of dose linearity. Comparison of fetal arterial peak concentrations as presented in Table I Figure 2 illustrates the time course of digoxin concentrations in a single animal. Linearity is demonstrated by the "fetal extraction ratio," calculated as one minus the ratio of umbilical venous to descending aortic concentrations. Such measurements were available 4 h after dosing in five fetuses that received the high dose and in six that received the low dose. The mean fetal extraction ratios were 0.10 f 0.17 and 0.10 + 0.13 for the high and low doses, respectively. In each group one fetus exhibited a negative extraction, i.e. venous concentrations exceeded aortic. If these values are omitted, the high-and low-dose extraction ratios average 0.16 a 0.11 and 0.14 + 0.08, respectively, suggesting similar digoxin elimination rates at both high and low doses.
We measured heart rate and blood pressure in the fetal aorta before and after injecting digoxin in both groups. Initially, heart rate and blood pressure in the high-dose group were 196 + 341 min and 5.8 + 0.4 kPa, respectively; in the low-dose group heart rate was 190 + 34/min and blood pressure was 6.2 f 0.7 kPa.
Neither heart rate nor blood pressure changed significantly throughout the observation period.
DISCUSSION
Multiple reports (2-8) have been published since Lingman et al. (1) first described successful transplacental treatment to convert supraventricular tachycardia to sinus rhythm with digoxin. In almost all of these reports, digoxin was administered to mother. But placental transfer of digoxin is erratic, varying not only among the previous case reports (1-5, 7, 8) but also among studies (9-1 1). In one case report (2) , the concentration of digoxin in umbilical cord blood was about one-fourth the concentration in maternal blood; in another (3), digoxin concentration in umbilical cord blood was almost the same as that in maternal blood. Furthermore, in some cases (4, 8) the dose of digoxin had to be reduced to avert maternal toxicity. Direct fetal administration of digoxin has been reported recently (12, 13) . Although this mode of therapy effectively converted tachycardia to normal sinus rhythm, fetal digoxin administration is impractical because it requires multiple intrafetal injections to maintain the digoxin concentration.
We showed that intraamniotic injection of digoxin increased fetal digoxin concentrations within the therapeutic range for a prolonged period of time. The digoxin concentration measurements suggest that digoxin was transferred directly from amniotic fluid to the fetal circulation as has been shown previously for thyroxine (17) and @-blocking agents (18) . Maternal digoxin concentrations were always significantly lower than fetal meas- Fig. 2 . Time-course of digoxin concentrations in fetal plasma and amniotic fluid. In a single animal (no. 4, low-dose group), this graph illustrates the relationship between concentrations of digoxin in amniotic fluid, the descending aorta, and the umbilical vein following intraamniotic injection of 0.24 nmol digoxin/kg fetal body wt. Note that at all time points, the digoxin concentration in the descending aorta was greater than in the umbilical vein and the concentration in amniotic fluid was about 150 times that in fetal plasma.
urements so transplacental transfer of digoxin likely proceeded in the fetal-to-maternal direction.
Singh et al. (1 1) and Berman et al. (19) investigated the elimination kinetics of digoxin administered i.v. in maternal and fetal sheep. Both reports showed that the fetal digoxin concentration declined quickly after bolus injection or cessation of an infusion. In our study, fetal digoxin concentration decreased slowly after intraamniotic bolus injection in a manner consistent with slow absorption from another compartment. Absorption of digoxin by the fetus from amniotic fluid could occur by swallowing. However, fetal swallowing does not occur continuously, and intervals between swallowing have been reported to be as long as 2.31 h (20) . Given the improbability that each fetus swallowed at the beginning of our study, swallowing is unlikely to be the only mechanism of digoxin absorption by the fetus from amniotic fluid. Furthermore, in one fetus, we ligated the esophagus to eliminate the possibility of swallowing and injected digoxin into the amniotic cavity. In this fetus, the digoxin concentration curve over time was similar to that of other fetuses and the peak concentration achieved was 3.6 nmol/L. In a recent preliminary communication, Gilbert et al. (21) reported that fetal plasma concentrations of arginine vasopressin increased in esophagealligated fetuses after intraamniotic injection of arginine vasopressin. Skin is a possible route of digoxin absorption because arterial digoxin concentrations exceeded umbilical venous. However, fetal skin is covered with hair at this stage of gestation, making significant transdermal diffusion unlikely. One other possible pathway is the interface between the amniotic fluid and fetal vessels in the amniotic membrane or near the placenta. If significant uptake occurred near the placenta, we should have detected higher, rather than lower, concentrations of digoxin in the umbilical vein than in the descending aorta. Although the exact site of digoxin absorption into the fetal circulation is unknown, it is apparent that the site where venous drainage from this area returns to the fetus is downstream from the umbilical veins.
Amniotic fluid containing a high concentration of digoxin could act as a reservoir that sustains an adequate digoxin level in the fetus. Therefore, intraamniotic administration of digoxin should be considered as a possible treatment for fetal congestive heart failure associated with tachyarrhythmia when the condition either does not respond to maternally administered antiarrhythmic agents or cannot be treated because elevated drug concentrations would result in maternal toxicity. Because there are considerable species differences in placental and amniotic membrane anatomy and transport, it is most important to determine the pharmacokinetics of intraamniotically administered digoxin in the pregnant woman before clinical use can be recommended.
